Eli Lilly Surges On Guidance Boost After Weight-Loss Drug Obliterates Sales Views
Investor's Business DailyEli Lilly stock jumped Tuesday despite a mixed first-quarter report, after sales of weight-loss drug Zepbound obliterated expectations.
The post Eli Lilly Surges On Guidance Boost After Weight-Loss Drug Obliterates Sales Views appeared first on Investo…